ALIM - アリメラ・サイエンシ―ズ （Alimera Sciences Inc.） アリメラ・サイエンシ―ズALIMのチャート
ALIMの企業情報
| symbol | ALIM |
|---|---|
| 会社名 | Alimera Sciences Inc. （アリメラ・サイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アリメラ・サイエンシーズ(Alimera Sciences Inc.)は処方眼科医薬品の研究・開発・商業化を専門に扱うバイオ医薬品企業。同社は眼底や網膜に影響を与える疾患を中心に取り扱う。同社の製品候補「ILUVIEN」は非外科的治療手順であり、25ゲージ針付きのデバイスを採用し、傷のセルフシールを可能にする。また、「ILUVIEN」はドライ型加齢黄斑変性症（AMD）、ウェット型AMD及び網膜静脈閉塞症（RVO）を治療するために３つの第２相臨床試験で研究されている。「ILUVIEN」は硝子体内インプラントであり、非独占の副腎皮質ステロイドであるフルオシノロンアセトニド（FAc）の持続的なサブマイクログラムレベルを提供することにより、糖尿病性黄斑浮腫（DME）に関連する視力障害の治療で最大36ヶ月の治療効果を提供する。 アリメラ・サイエンシ―ズは米国のバイオ医薬品メ―カ―。眼科薬の研究、開発、商業化に従事。主に、眼球の裏側や網膜に影響を及ぼす疾患に焦点を当てている。慢性糖尿病性黄斑浮腫に関連した視力障害治療薬「イルビエン」は、英国、オ―ストリア、ポルトガル、フランス、ドイツ、スペインで販売承認を受けている。本社はジョ―ジア州。 Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA. |
| 本社所在地 | 6120 Windward Parkway Suite 290 Alpharetta GA 30005 USA |
| 代表者氏名 | Richard S. Eiswirth リチャードエスワース |
| 代表者役職名 | President Chief Financial Officer |
| 電話番号 | +1 678-990-5740 |
| 設立年月日 | 37773 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 126人 |
| url | www.alimerasciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alim |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.46000 |
| 終値（lastsale） | 0.931 |
| 時価総額（marketcap） | 65205760.641 |
| 時価総額 | 時価総額（百万ドル） 66.07424 |
| 売上高 | 売上高（百万ドル） 39.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 156.19224 |
| 当期純利益 | 当期純利益（百万ドル） -24.19300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alimera Sciences Inc revenues increased 22% to $20.7M. Net loss increased 23% to $11.7M. Revenues reflect United States segment increase of 20% to $15M International segment increase of 28% to $5.7M. Higher net loss reflects United States segment loss increase of 21% to $2.7M International segment loss increase of 27% to $1.2M. |
ALIMのテクニカル分析
ALIMのニュース
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update 2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update 2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates 2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Refinances Debt Facility With Solar Capital 2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .
Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio 2019/11/07 23:00:00 Yahoo Finance
Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse split) of its common stock that will become effective on
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates 2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Refinances Debt Facility With Solar Capital 2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .
Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio 2019/11/07 23:00:00 Yahoo Finance
Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse split) of its common stock that will become effective on
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books 2019/09/04 11:08:03 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO ) DURECT Corporation (NASDAQ: DRRX ) Insulet Corporation (NASDAQ: PODD ) ( announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) The Medicines Company (NASDAQ: MDCO ) (announced positive Phase 3 results for inclisiran) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 3) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aduro BioTech Inc (NASDAQ: ADRO ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Assembly Biosciences Inc (NASDAQ: ASMB ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Gemphire Therapeutics Inc (NASDAQ: …
The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved 2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates 2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Refinances Debt Facility With Solar Capital 2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .
Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio 2019/11/07 23:00:00 Yahoo Finance
Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse split) of its common stock that will become effective on
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books 2019/09/04 11:08:03 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO ) DURECT Corporation (NASDAQ: DRRX ) Insulet Corporation (NASDAQ: PODD ) ( announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) The Medicines Company (NASDAQ: MDCO ) (announced positive Phase 3 results for inclisiran) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 3) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aduro BioTech Inc (NASDAQ: ADRO ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Assembly Biosciences Inc (NASDAQ: ASMB ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Gemphire Therapeutics Inc (NASDAQ: …
The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved 2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …